Thyrocare Technologies Limited , a leading diagnostics company, has announced a significant corporate action that includes a bonus share issue and an increase in authorized share capital. The company's board has approved these measures, which are now subject to shareholder approval through a postal ballot.

Key Highlights

• Bonus Share Issue: Thyrocare proposes a 2:1 bonus share issue, where shareholders will receive two new fully paid-up equity shares for every one existing share held.
• Increase in Authorized Share Capital: The company plans to increase its authorized share capital from Rs. 100 crores to Rs. 300 crores.
• Capitalization of Reserves: Approximately Rs. 106.11 crores will be capitalized from the company's reserves for the bonus issue.
• Articles of Association: The company seeks approval to alter its Articles of Association to accommodate these changes.

Bonus Share Issue Details

Thyrocare's board has recommended a bonus issue in the ratio of 2:1, subject to shareholder approval. This means that for every one existing fully paid-up equity share of Rs. 10 each, shareholders will receive two new fully paid-up equity shares of Rs. 10 each. This move is described as a gesture of appreciation to shareholders during the company's Silver Jubilee year and coincides with Diwali celebrations.

Increase in Authorized Share Capital

To facilitate the bonus issue and future requirements, Thyrocare proposes to increase its authorized share capital as follows:

This increase will be achieved by creating an additional 20 crore equity shares of Rs. 10 each.

Postal Ballot and E-voting Details

Shareholders will vote on these proposals through a postal ballot. The key dates for the e-voting process are:

• E-voting Start Date: October 18, 2025
• E-voting End Date: November 16, 2025
• Results Declaration: By November 18, 2025

Impact on Employee Stock Options

The company has stated that appropriate adjustments will be made to the exercise price and/or the number of shares to be issued against employee stock options. This is to ensure that the total value of the employee stock options remains unchanged after the bonus issuance.

Conclusion

Thyrocare Technologies' proposed bonus issue and capital increase reflect the company's financial position and its commitment to rewarding shareholders. These corporate actions, if approved, may enhance the liquidity of the company's shares in the stock market and potentially benefit long-term shareholders.

Investors and shareholders are advised to carefully review the postal ballot notice and cast their votes accordingly. The implementation of these proposals is subject to obtaining necessary regulatory approvals and shareholder consent.

Thyrocare Technologies , a leading diagnostic company, saw its shares surge 16% to Rs 1,470 on Tuesday, reaching a fresh 52-week high following the announcement of robust Q2 results. The company's performance was marked by significant growth across key financial metrics and strategic initiatives.

Financial Highlights

Thyrocare reported an impressive 82% year-on-year growth in profit after tax, which stood at Rs 47.90 crore for the quarter. The company's revenue increased by 22% to Rs 216.53 crore, while normalized EBITDA rose 49% to Rs 75.36 crore.

Key financial metrics for Q2:

The company maintained steady margins, with EBITDA margin at 35% and gross margin at 72%.

Operational Performance

Thyrocare's growth was primarily driven by a 24% increase in the Pathology segment. The company's franchise revenue grew by 20%, while partnership revenue surged by 35% year-on-year. During the quarter, Thyrocare processed 53.3 million tests, marking a substantial 21% increase compared to the same period last year.

Network Expansion

As part of its growth strategy, Thyrocare expanded its network by adding four new laboratories in Vijayawada, Bhagalpur, Roorkee, and Kashmir during H1. This expansion is expected to enhance the company's regional presence and improve service accessibility.

Bonus Share Issue and Dividend

In a move to reward shareholders, Thyrocare's Board of Directors has approved and recommended a bonus issue of shares in the ratio of 2:1, subject to shareholder and regulatory approvals. This means shareholders will receive two new fully paid-up equity shares for every one share held.

Additionally, the Board declared an interim dividend of Rs 7 per equity share (face value Rs 10). The record date for determining shareholder eligibility for the interim dividend is set for October 24.

Management Commentary

Rahul Guha, Managing Director of Thyrocare Technologies, commented on the results: "We are pleased to report a robust set of results for the quarter and the announcement of our bonus issue on the occasion of 25 years of Thyrocare coinciding with the auspicious occasion of Diwali. These numbers underscore our continued focus on operational excellence, network expansion, and value-driven diagnostics."

Financial Position

Thyrocare continues to maintain a strong balance sheet, remaining debt-free on a consolidated basis. The company reported net cash and short-term investments exceeding Rs 190 crore as of September 30.

Outlook

With its strong financial performance, network expansion, and shareholder-friendly initiatives, Thyrocare Technologies appears well-positioned for continued growth in the diagnostic services sector. The company's focus on deepening its presence in underserved regions and scaling its franchise and partner channels is likely to drive future growth.

Investors and analysts will be watching closely to see if Thyrocare can maintain this growth momentum in the coming quarters, especially given the competitive landscape in the diagnostic services industry.